ASP3652 clinical trials
Also written ASP3652.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses ASP3652 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ASP3652
- 8
Studies by the year they started
8 studies that test it; most in 2012 (6)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ASP3652 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)CompletedPhase 2Astellas Pharma Europe B.V.NCT01613586Written as ASP3652
- A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652CompletedPhase 1Astellas Pharma Europe B.V.NCT02243657Written as ASP3652
- A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652CompletedPhase 1Astellas Pharma Europe B.V.NCT02046798Written as ASP3652
- A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male SubjectsCompletedPhase 1Astellas Pharma Europe B.V.NCT02034734Written as ASP3652
- A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and TolerabilityCompletedPhase 1Astellas Pharma Europe B.V.NCT01958047Written as ASP3652
- A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy SubjectsCompletedPhase 1Astellas Pharma Europe B.V.NCT01815684Written as ASP3652
- A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)CompletedPhase 2Astellas Pharma IncNCT01391338Written as ASP3652
- A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy SubjectsCompletedPhase 1Astellas Pharma Europe B.V.NCT01797198Written as ASP3652